VALN - Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data | Benzinga
Monday, Valneva SE (NASDAQ:VALN) released further Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine.
Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination with a single dose of the vaccine.
The Day 180 results confirm the initial immunogenicity and safety data Valneva reported previously and are intended to support filing for potential label extension for use ...